S-1: Scorpius Holdings Seeks $14.4 Million in Public Offering Amidst NYSE American Delisting Appeal

Scorpius Holdings files for a public offering of common stock and pre-funded warrants to raise approximately $11.1 million net proceeds, while simultaneously appealing its delisting from the NYSE American.

Summary

• Scorpius Holdings, a contract development and manufacturing organization (CDMO), is undertaking a firm commitment public offering of 3,125,000 shares of common stock and pre-funded warrants to purchase up to 3,125,000 shares.
• The offering is based on an assumed public offering price of $4.00 per share, which is based on the last reported sales price of the common stock on the OTC Markets on July 10, 2024, adjusted for a 1-for-200 reverse stock split.
• The company intends to use the net proceeds of approximately $11.1 million to fund working capital, general corporate purposes, and the repayment of a $750,000 note.
• Scorpius Holdings' common stock is currently trading on the OTC Markets under the symbol 'SCPX' after receiving notice from the NYSE Regulation that it had suspended trading of its common stock on the NYSE American and determined to commence proceedings to delist its common stock from the NYSE American.
• The company has appealed this determination, with a hearing scheduled for August 7, 2024.
• The company effected a 1-for-200 reverse stock split on July 17, 2024, to increase the selling price of its common stock in order to regain compliance with NYSE American requirements.
• The company had an accumulated deficit of $258.8 million as of March 31, 2024, and a net loss of approximately $4.7 million for the three months ended March 31, 2024.
• The company expects its current cash and cash equivalents and short term investments to support its operations beyond early August 2024.
• Even if the company raises the maximum amount being offered, its cash, together with the proceeds of this offering, is not expected to last beyond November 2024 unless its revenue increases from past historical revenue.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial struggles, delisting concerns, and limited cash runway. While the capital raise provides some relief, the overall outlook is uncertain.

Positives

• The offering provides Scorpius Holdings with additional capital to fund its operations and repay debt.
• The company is actively appealing its delisting from the NYSE American.
• The reverse stock split is an attempt to regain compliance with NYSE American listing requirements.
• The company's San Antonio, TX facility commenced operations in October 2022.

Negatives

• The company is facing delisting from the NYSE American due to a low stock price.
• Scorpius Holdings has a significant accumulated deficit and has been experiencing net losses.
• The company's cash runway is limited, with current funds expected to last only until early August 2024.
• The company's cash, together with the proceeds of this offering, is not expected to last beyond November 2024 unless its revenue increases from past historical revenue.
• There is no guarantee that the appeal of the NYSE Regulation staff's decision will be successful.
• There is no guarantee that the 2024 Reverse Stock Split will increase the stock price sufficiently in order to meet any requirements and policies of the NYSE American.

Risks

• The company's consolidated financial statements have been prepared assuming that it will continue as a going concern, but there is substantial doubt about its ability to do so.
• The company may not be able to raise additional capital on acceptable terms, or at all.
• The company's management has broad discretion in using the net proceeds from this offering.
• There is no public market for the pre-funded warrants being offered.
• The company's failure to have its common stock traded on a national securities exchange will adversely impact its common stock.
• The 2024 Reverse Stock Split may decrease the liquidity of the shares of the company's common stock.

Future Outlook

The company believes the net proceeds of this offering will fund its operations through November 2024 after the closing of this offering.

Industry Context

Scorpius Holdings operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to the increasing demand for outsourced manufacturing services from biotechnology and biopharmaceutical companies. The company focuses on biologics manufacturing, including celland gene-based therapies, which are high-growth areas within the CDMO market.

Comparison to Industry Standards

• It is difficult to compare Scorpius Holdings directly to industry standards without more detailed financial information and specific performance metrics.
• However, some publicly traded CDMOs, such as Lonza, Catalent, and Thermo Fisher Scientific, serve as benchmarks for revenue generation, profitability, and growth rates.
• These larger CDMOs typically have diversified service offerings and a global presence, which may provide them with a more stable revenue base compared to smaller, more specialized CDMOs like Scorpius.
• The company's ability to secure long-term contracts and maintain high utilization rates at its San Antonio facility will be critical for achieving sustainable growth and profitability.
• The company's focus on cell and gene therapies aligns with a high-growth segment of the CDMO market, but also requires specialized expertise and capabilities.

Related Party Transactions

• On January 26, 2024, the company issued a convertible promissory note in the aggregate amount of $2,250,000 to Elusys Holdings, Inc.
• On May 1, 2024, the company issued a 1% non-convertible promissory note due July 31, 2024 in the principal amount of $750,000 to Elusys Holdings, Inc.
• On May 1, 2024, the company issued an amended and restated 1% convertible promissory note in the principal amount of $2,250,000 to Elusys Holdings, Inc.

Stakeholder Impact

• Shareholders face potential dilution from the public offering.
• Employees face uncertainty due to the company's financial struggles and potential restructuring.
• Customers may be concerned about the company's ability to fulfill its contractual obligations.
• Suppliers may face increased risk of non-payment.
• Creditors face increased risk of default.

Next Steps

• The company will proceed with the public offering, subject to market conditions and regulatory approvals.
• The company will continue to pursue its appeal of the NYSE American delisting.
• The company will focus on securing long-term contracts and increasing utilization rates at its San Antonio facility.
• The company will monitor its cash flow and explore additional financing options if needed.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, reverse stock split, NYSE American, delisting, OTC Markets, CDMO, biologics manufacturing, Scorpius Holdings